Signal active
Contact Information
Social
Primary Organization
2017
11-50
Biotechnology, Health Care, Therapeutics
Bio
After obtaining her MSc in Medical Biotechnology at the University of Torino, Federica worked in the group led by Paolo Michieli at the Candiolo Cancer Institute where, through a close collaboration with argenx, she generated, screened and characterized the MET-agonistic antibodies that represent the first asset of AgomAb. Expert in the generation of monoclonal antibodies through phage display and single B-cell cloning technologies, Federica joined argenx in 2015 where she has worked as Associate Scientist until the end of 2018. At argenx she has actively contributed to the development of several drug candidates, some of which are now in the clinic.
Location
Leiden, Zuid-Holland, The Netherlands, Europe
Jobs history
1
AgomAb Therapeutics
Co-founder
Invalid date - Current
Educations
1
N/A
Profile Resume
Federica Linty is the Co-founder at AgomAb Therapeutics, based in Europe. With a background in Biotechnology, Federica Linty has a rich history of leadership and innovation. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Recommendation from your interest
N/A
Products and Innovations
0
There is no product and inovations for this profile.
Achievements
0
There is no Achievements for this profile.
Publications
0
There is no publication for this profile.
Recent Activity
There is no recent news or activity for this profile.